-
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.
Nat Med. 2000 Feb;6(2):200-6
PMID: 10655110
-
Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.
J Virol. 1997 Oct;71(10):7198-206
PMID: 9311792
-
Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273).
J Infect Dis. 2000 Feb;181(2):548-54
PMID: 10669338
-
Metabolic properties of IgG subclasses in man.
J Clin Invest. 1970 Apr;49(4):673-80
PMID: 5443170
-
The G4 subclass in IgG fractions prepared by ion-exchange chromatography.
J Immunol. 1970 May;104(5):1310-2
PMID: 4986370
-
Papain sensitivity of heavy chain sub-classes in normal human IgG and localizaton of antigenic determinants for the sub-classes.
Immunochemistry. 1971 Mar;8(3):243-50
PMID: 4113947
-
Primary structure of the "hinge" region of human IgG3. Probable quadruplication of a 15-amino acid residue basic unit.
J Biol Chem. 1977 Feb 10;252(3):883-9
PMID: 402363
-
Immune globulins.
Semin Thromb Hemost. 1979;6(1):44-74
PMID: 117551
-
pH gradient elution of human IgG1, IgG2 and IgG4 from protein A-sepharose.
J Immunol Methods. 1979;31(3-4):211-7
PMID: 42659
-
IgG subclasses in human gamma-globulin preparations for intravenous use and their reactivity with staphylococcus protein A.
Vox Sang. 1980;38(3):147-55
PMID: 6155736
-
Prophylaxis of varicella in high-risk children: dose-response effect of zoster immune globulin.
J Pediatr. 1981 Mar;98(3):368-73
PMID: 7205447
-
Correlation between segmental flexibility and effector function of antibodies.
Nature. 1984 Jan 12-18;307(5947):136-40
PMID: 6690993
-
Antibody-antigen flexibility.
Nature. 1987 Mar 26-Apr 1;326(6111):334-5
PMID: 3561477
-
Intravenous immunoglobulins as therapeutic agents.
Ann Intern Med. 1987 Sep;107(3):367-82
PMID: 3304051
-
Differences among available immunoglobulin preparations for intravenous use.
Pediatr Infect Dis J. 1988 May;7(5 Suppl):S43-8
PMID: 2456510
-
Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies.
EMBO J. 1988 Jul;7(7):1989-94
PMID: 3138110
-
Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
Nature. 1990 Jun 14;345(6276):622-5
PMID: 2190095
-
Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.
J Virol. 1991 Jan;65(1):31-41
PMID: 1985202
-
Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors.
Blood. 1991 Mar 1;77(5):1111-7
PMID: 1995097
-
Prevention of HIV infection by passive immunization with HIV immunoglobulin.
AIDS Res Hum Retroviruses. 1991 Dec;7(12):971-3
PMID: 1812946
-
Intermolecular cooperativity: a clue to why mice have IgG3?
Immunol Today. 1992 May;13(5):164-8
PMID: 1642754
-
Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis.
AIDS Res Hum Retroviruses. 1992 May;8(5):553-8
PMID: 1381201
-
An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1.
J Virol. 1992 Dec;66(12):7517-21
PMID: 1433527
-
Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody.
J Virol. 1992 Dec;66(12):7538-42
PMID: 1433529
-
Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.
J Virol. 1997 Nov;71(11):8141-8
PMID: 9343164
-
beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques.
Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10803-8
PMID: 9724785
-
Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells.
J Virol. 1998 Dec;72(12):9788-94
PMID: 9811714
-
Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.
Nat Med. 1999 Feb;5(2):204-10
PMID: 9930869
-
Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185.
J Infect Dis. 1999 Mar;179(3):567-75
PMID: 9952362
-
Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.
J Virol. 1999 May;73(5):4009-18
PMID: 10196297
-
Prevention of HIV infection by passive immunization with HIVIG or CD4-IgG.
AIDS Res Hum Retroviruses. 1992 Aug;8(8):1515
PMID: 1466993
-
Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.
J Immunol. 1993 Jan 15;150(2):635-43
PMID: 7678279
-
A human lymphoid recombinant cell line with functional human immunodeficiency virus type 1 envelope.
AIDS Res Hum Retroviruses. 1993 Jan;9(1):23-32
PMID: 8094000
-
Role of heavy chain constant domains in antibody-antigen interaction. Apparent specificity differences among streptococcal IgG antibodies expressing identical variable domains.
J Immunol. 1993 Mar 15;150(6):2231-42
PMID: 7680687
-
Variable domain-identical antibodies exhibit IgG subclass-related differences in affinity and kinetic constants as determined by surface plasmon resonance.
Mol Immunol. 1994 Jun;31(8):577-84
PMID: 7515151
-
HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.
Vaccine. 1994 Sep;12(12):1141-8
PMID: 7998425
-
Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1.
J Virol. 1995 Jun;69(6):3712-20
PMID: 7745720
-
Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo.
J Virol. 1995 Jul;69(7):4453-62
PMID: 7769705
-
Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+ T-cell lines vs. primary macrophages.
Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):9004-8
PMID: 7568061
-
Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody.
J Immunol. 1995 Oct 1;155(7):3638-44
PMID: 7561063
-
Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo.
J Immunol. 1996 Aug 15;157(4):1791-8
PMID: 8759769
-
Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group.
J Infect Dis. 1997 Feb;175(2):283-91
PMID: 9203648
-
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
Nat Med. 2000 Feb;6(2):207-10
PMID: 10655111